{
  "source": "PA-Med-Nec-Rinvoq-Rinvoq_LQ.txt",
  "chunks": [
    "(UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2202-15\nProgram Prior Authorization/Medical Necessity\nMedication Rinvoq® (upadacitinib) extended-release tablets/ Rinvoq® LQ (upadacitinib)\noral solution\nP&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 2/2022, 3/2022, 5/2022, 6/2022, 7/2022,\n12/2022, 7/2023, 9/2023, 6/2024, 4/2025, 6/2025\nEffective Date 8/17/2025\n1. Background:\nRinvoq is a Janus kinase (JAK) inhibitor. Rinvoq and/or Rinvoq LQ is indicated for the treatment of:\n• Adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate\nresponse or intolerance to one or more TNF tumor necrosis factor (TNF) blockers.\nLimitation of Use:\nThe use of Rinvoq in combination with other JAK inhibitors, biologic DMARDs, or with potent\nimmunosuppressants such as azathioprine and cyclosporine is not recommended.\n• Adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have an\ninadequate response or intolerance to one or more TNF blockers.\nLimitation of Use:\nRinvoq/Rinvoq LQ is not recommended for use in combination with other JAK inhibitors,\nbiologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic\ndermatitis whose disease is not adequately controlled with other systemic drug products,\nincluding biologics, or when use of those therapies are inadvisable.\nLimitation of Use:\nRinvoq is not recommended in combination with other JAK inhibitors, biologic\nimmunomodulators, or with other immunosuppressants.\n• Adults with moderately to severely active ulcerative colitis who have had an inadequate response\nor intolerance to one or more TNF blockers.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biological\ntherapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and\ncyclospo",
    " Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biological\ntherapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and\ncyclosporine.\nRinvoq should be discontinued if adequate therapeutic response is not achieved with the 30 mg\ndosage. Use the lowest effective dosage needed to maintain response.\n• Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to\none or more TNF blockers.\n© 2025 UnitedHealthcare Services, Inc.\n1\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation\nwho have had an inadequate response or intolerance to TNF blocker therapy.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with moderately to severely active Crohn’s disease who have had an inadequate response\nor intolerance to one or more TNF blockers.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biological\ntherapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and\ncyclosporine\n• Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have\nan inadequate response or intolerance to one or more TNF blockers.\nLimitation of Use:\nRinvoq/Rinvoq LQ is not recommended for use in combination with other JAK inhibitors,\nbiologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with giant cell arteritis.\nLimitation of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and ",
    "s with giant cell arteritis.\nLimitation of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active RA\n-AND-\n(2) One of the following:\n(a) Both of the following\ni. One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n• History of failure to a 3 month trial of one non-biologic disease\nmodifying anti-rheumatic drug (DMARD) [e.g., methotrexate,\nleflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated\ndoses, unless contraindicated or clinically significant adverse effects are\nexperienced (document drug, date and duration of trial)b\n-OR-\n• Patient has been previously treated with targeted immunomodulator FDA-\napproved for the treatment of rheumatoid arthritis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nadalimumab, Simponi (golimumab), Orencia (abatacept), Olumiant\n(baricitinib), Xeljanz/Xeljanz XR (tofacitinib)]\n-AND-\nii. One of the following:\n• History of failure, contraindication, or intolerance to at least one TNF\ninhibitor^\n-OR-\n• Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria6).\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed ",
    "not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\n© 2025 UnitedHealthcare Services, Inc.\n3\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Abbvie sponsored Rinvoq Complete program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) Both of the following\ni. One of the following:\n• History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless c",
    "ive psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) Both of the following\ni. One of the following:\n• History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n© 2025 UnitedHealthcare Services, Inc.\n4\n-OR-\n• Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of psoriatic arthritis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nadalimumab, Simponi (golimumab), Orencia (abatacept), Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Olumiant (baricitinib), Otezla\n(apremilast)Xeljanz/Xeljanz XR (tofacitinib)]\n-AND-\nii. One of the following:\n• History of failure, contraindication, or intolerance to at least one TNF\ninhibitor ^\n-OR-\n• Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria6).\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq or Rinvoq LQ therapy as documented by claims\nhistory or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Rinvoq or Rinvoq LQ*\n-AND-\n(3) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinu",
    " LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]\n© 2025 UnitedHealthcare Services, Inc.\n5\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Abbvie sponsored Rinvoq Complete program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq or Rinvoq LQ therapy\n-AND-\n(2) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nC. Atopic Dermatitis\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. History of failure, contraindication, or intolerance to two of the following\n© 2025 UnitedHealthcare Servi",
    "evere chronic atopic dermatitis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. History of failure, contraindication, or intolerance to two of the following\n© 2025 UnitedHealthcare Services, Inc.\n6\ntherapeutic classes of topical therapies (document drug, date of trial, and/ or\ncontraindication to medication):\na. Medium to very-high potency topical corticosteroid [e.g., Elocon\n(mometasone furoate), Synalar (fluocinolone acetonide), Lidex\n(fluocinonide)]\nb. Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)].¥\nc. Eucrisa (crisaborole) ¥\n-AND-\nii. One of the following:\na. Both of the following^:\n• Submission of medical records (e.g., chart notes, laboratory values)\ndocumenting a 3 month trial b of a systemic drug product for the\ntreatment of atopic dermatitis [examples include, but are not limited\nto, Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Ebglyss\n(lebrikizumab-lbkz), etc.Ω] (prescription claims history may be used\nin conjunction as documentation of medication use, dose, and\nduration)\n-AND-\n• Physician attests that the patient was not adequately controlled with\nthe documented systemic drug product\n-OR-\nb. Physician attests that systemic treatment with all of the following, FDA-\napproved chronic atopic dermatitis therapies is inadvisable. (Document\ndrug and contraindication rationale) ^\n• Adbry (tralokinumab-ldrm)\n• Dupixent (dupilumab)\n• Ebglyss (lebrikizumab-lbkz)\n-OR-\nc. Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria6).\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq therapy as documented by claims history or\n© 2025 UnitedHealthcare Services, Inc.\n7\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assis",
    ".\n7\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored Rinvoq\nComplete program (e.g., sample card which can be redeemed at a pharmacy for\na free supply of medication) as a means to establish as a current user of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Cibinqo (abrocitinib), Ebglyss (lebrikizumab-lbkz), Nemluvio\n(nemolizumab-ilto), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura\n(topical ruxolitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Abbvie sponsored Rinvoq Complete program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Cibinqo (abrocitinib), Ebglyss (lebrikizumab-lbkz), Nemluvio\n(nemolizumab-ilto), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura\n(topical ruxolitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\n© 2025 UnitedHealthcare Services, Inc.\n8\nmofetil)\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Dermatologist\n(b) All",
    "ssant (e.g., azathioprine, cyclosporine, mycophenolate\n© 2025 UnitedHealthcare Services, Inc.\n8\nmofetil)\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active UC\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\n• Patient has had prior or concurrent inadequate response to a therapeutic\ncourse of oral corticosteroids and/or immunosuppressants (e.g.,\nazathioprine, 6-mercaptopurine)\n-OR-\n• Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of ulcerative colitis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., adalimumab, Simponi (golimumab), Stelara\n(ustekinumab), Xeljanz/XR (tofacitinib)]\n-AND-\nii. One of the following:\n• History of failure, contraindication, or intolerance to at least one TNF\ninhibitor^\n-OR-\n• Patient has a documented needle-phobia to the degree that the patient has\n© 2025 UnitedHealthcare Services, Inc.\n9\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria5).\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq therapy as documented by claims history or\nsubmission of medical records (Document drug, date, and duration of therapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored Rinvoq\nComplete program (e.g., sample card which can be redeemed at a pharmacy for\na free supply of medication) as a means to establish as a current user of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted",
    " at a pharmacy for\na free supply of medication) as a means to establish as a current user of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Abbvie sponsored Rinvoq Complete program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\n© 2025 UnitedHealthcare Services, Inc.\n10\nOlumiant (baricitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nE. Ankylosing Spondylitis and non-radiographic Axial Spondyloarthritis (nr-axSpA)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or non-radiographic axial\nspondyloarthritis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\n• History of failure to two NSAIDs (e.g., ibuprofen, naproxen) ",
    "ndylitis or non-radiographic axial\nspondyloarthritis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\n• History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at\nmaximally indicated doses, each used for at least 4 weeks, unless\ncontraindicated or clinically significant adverse effects are\nexperienced (document drug, date, and duration of trial)\n-OR-\n• Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of ankylosing spondylitis or non-\nradiographic axial spondyloarthritis as documented by claims history\nor submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nadalimumab, Simponi (golimumab), Xeljanz/Xeljanz XR\n(tofacitinib)]\n-AND-\nii. One of the following:\n• History of failure, contraindication, or intolerance to at least one TNF\ninhibitor^\n-OR-\n• Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria5).\n© 2025 UnitedHealthcare Services, Inc.\n11\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq therapy as documented by claims history or\nsubmission of medical records (Document drug, date, and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclo",
    "Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from the\nAbbvie sponsored Rinvoq Complete program shall be required to meet initial authorization criteria as\nif patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n© 2025 UnitedHealthcare Services, Inc.\n12\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nF. Crohn’s Disease (CD)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\n• History of failure to one of the following conventional therapies at up to\nmaximally indicated doses, unless contraindicated or clinically significant\nadverse effects are experienced (document drug, date, and duration of\ntrial):\n Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)\n 6-mercaptopurine (Purinethol)\n Azathioprine (Imuran)\n Methotrexate (Rheumatrex, Trexall)\n-OR-\n• Patient has been previously treated with a targeted immunomodulator\nFDA-",
    "ylprednisolone, budesonide)\n 6-mercaptopurine (Purinethol)\n Azathioprine (Imuran)\n Methotrexate (Rheumatrex, Trexall)\n-OR-\n• Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of Crohn’s disease as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., adalimumab, Cimzia (certolizumab),\nStelara (ustekinumab), Skyrizi (isankizumab)]\n-AND-\nii. One of the following:\n• History of failure, contraindication, or intolerance to at least one TNF\ninhibitor^\n-OR-\n• Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria5).\n© 2025 UnitedHealthcare Services, Inc.\n13\n-OR-\n(b) Both of the following:\ni. Patient is currently on Rinvoq therapy as documented by claims history or\nsubmission of medical records (Document drug, date, and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Rinvoq*\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance ",
    "terologist\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from the\nAbbvie sponsored Rinvoq Complete program shall be required to meet initial authorization criteria as\nif patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\n© 2025 UnitedHealthcare Services, Inc.\n14\nXeljanz (tofacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nG. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure, contraindication, or intolerance to at least one TNF\ninhibitor^\n-OR-\n(b) Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria5).\n-OR-\n(c) Both of the following:\ni. Patient is currently on Rinvoq or Rinvoq LQ therapy as documented by claims\nhistory or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which ",
    "ii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nRinvoq Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Rinvoq or Rinvoq LQ*\n-AND-\n(3) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\n© 2025 UnitedHealthcare Services, Inc.\n15\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\nXeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from the\nAbbvie sponsored Rinvoq Complete program shall be required to meet initial authorization criteria as\nif patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq or Rinvoq LQ therapy\n-AND-\n(2) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\nXeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nH. Giant Cell Arteritis (GCA)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of giant cell arteritis\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either o",
    "1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of giant cell arteritis\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\ntocilizumab, Xeljanz (tofacitinib)]\n© 2025 UnitedHealthcare Services, Inc.\n16\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\ntocilizumab, Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n^ Tried/failed alternative(s) are supported by FDA labeling\n¥ Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.\nTable 1: Relative potencies of topical corticosteroids8\nClass Drug Dosage Form Strength (%)\nAugmented betamethasone Ointment, gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented bet",
    "\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cream, lotion 0.05\ndipropionate\nBetamethasone dipropionate Cream, foam, ointment, solution 0.05\nHigh Potency\nDesoximetasone Cream, ointment 0.25\nDesoximetasone Gel 0.05\nDiflorasone diacetate Cream 0.05\nFluocinonide Cream, gel, ointment, solution 0.05\n© 2025 UnitedHealthcare Services, Inc.\n17\nHalcinonide Cream, ointment 0.1\nMometasone furoate Ointment 0.1\nTriamcinolone acetonide Cream, ointment 0.5\nBetamethasone valerate Cream, foam, lotion, ointment 0.1\nClocortolone pivalate Cream 0.1\nDesoximetasone Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometasone furoate Cream, lotion 0.1\nTriamcinolone acetonide Cream, ointment, lotion 0.1\nHydrocortisone butyrate Cream, ointment, solution 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonide Cream, gel, foam, ointment 0.05\nFluocinolone acetonide Cream, solution 0.01\nDexamethasone Cream 0.1\nLowest\nHydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1\npotency\nHydrocortisone acetate Cream, ointment 0.5-1\nTable 2: Systemic immunomodulatory agents recommended by the 2014 American Academy of\nDermatology guidelines for the treatment of refractory atopic dermatitis Ω,9\nCyclosporine\nAzathioprine\nMethotrexate\nMycophenolate mofetil\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic cla",
    "thorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Rinvoq [package insert]. North Chicago, IL: AbbVie Inc.; April 2025.\n2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline\nfor the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.\n2021;73(7):924-939.\n3. Cohen S, Mikuls TR. Initial treatment of rheumatoid arthritis in adults. In: Post TW, ed.\nUpToDate. UpToDate; 2021. Accessed on December 17th, 2021.\n4. Sing JA, Guyatt G, Ogie A, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Guideline for the Treatment of Psoriatic Arthritis.\n© 2025 UnitedHealthcare Services, Inc.\n18\n5. Gladman DD, Ritchlin C. Treatment of psoriatic arthritis. In: Post TW, ed. UpToDate.\nUpToDate; 2021. Accessed on December 17th, 2021.\n6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth\nEdition, Arlington, VA: American Psychiatric Publishing. 2013.\n7. Eichenfield LF, Tom WL, Chamlin SL et al. Guidelines of care for the management of atopic\ndermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol.\n2014; 70(1):338-51.\n8. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic\ndermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am\nAcad Dermatol. 2014; 71(1):116-32.\n9. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic\ndermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am\nAcad Dermatol. 2014 Aug;71(2):327-49.\nProgram Prior Authorization/Medical Necessity – Rinvoq (upadacitinib)/Rinvoq\nLQ\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement from fa",
    "14 Aug;71(2):327-49.\nProgram Prior Authorization/Medical Necessity – Rinvoq (upadacitinib)/Rinvoq\nLQ\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement from failure\ncriteria. Removed prescriber requirement from reauthorization criteria.\nReference updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n12/2021 Updated conventional DMARD bypass language for rheumatoid\narthritis with no change to clinical intent. Updated CT/KY footnote.\n2/2022 Added step through a TNF inhibitor for RA and coverage criteria for\nPsA per updated label. Updated background and references. Added\nfootnote to support FDA labeled first line requirements.\n3/2022 Updated background and added coverage criteria for new indication for\natopic dermatitis. Updated references.\n5/2022 Updated background and added coverage criteria for new indication for\nulcerative colitis. Updated state mandate to include Mississippi.\nUpdated reference.\n6/2022 Updated background and added coverage criteria for new indication for\nankylosing spondylitis. Updated reference.\n7/2022 Removed age requirement from initial authorization criteria for atopic\ndermatitis.\n12/2022 Updated background and added coverage criteria for new indication for\nnon-radiographic axial spondyloarthritis. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples. Updated background and\nadded coverage criteria for crohn’s disease. Updated reference.\n9/2023 Updated examples. No change to coverage criteria.\n6/2024 Added Rinvoq LQ to the program. Updated criteria with pediatric\nindication for PsA. Added criteria for new indication for pJIA. Updated\nbackground, reference and state mandate footnote.\n4/2",
    "ia.\n6/2024 Added Rinvoq LQ to the program. Updated criteria with pediatric\nindication for PsA. Added criteria for new indication for pJIA. Updated\nbackground, reference and state mandate footnote.\n4/2025 Annual review. Added Ebglyss as an example of systemic drug\n© 2025 UnitedHealthcare Services, Inc.\n19\nproduct. Updated examples with no change to clinical intent.\n6/2025 Updated background and added coverage criteria for new indication for\nGiant Cell Arteritis (GCA). Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n20"
  ]
}